US
Udayan Sengupta
About Udayan Sengupta
Data last updated:
Udayan Sengupta is a Whole-Time Director at Scl Lifesciences Limited (since 2005). The company operates in Pharma. Scl Lifesciences Limited reported revenue of ₹305 Cr (FY 2026).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Whole-Time Director | 04 Oct 2005 | 1993 | ₹305 Cr (FY 2026) | Active |
Board colleagues of Udayan Sengupta
| Name | DIN | Company | Designation |
|---|---|---|---|
| Anil Chaudhry | 03213517 | Scl Lifesciences Limited | Director |
| Naohiro Yoshida | 09283051 | Scl Lifesciences Limited | Director |
| Nitish Mukherjee | 00561390 | Scl Lifesciences Limited | Director |
| Parveen Goyal | 00155519 | Scl Lifesciences Limited | Managing Director |
| Sameer Singla | 01072489 | Scl Lifesciences Limited | Director |
| Saurav Goyal | 08270604 | Scl Lifesciences Limited | Whole-Time Director |
| Shweta Mehta | 00158195 | Scl Lifesciences Limited | Director |
| Vijay Dilbagh Rai | 00075837 | Scl Lifesciences Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Udayan Sengupta
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Udayan Sengupta
Udayan Sengupta currently holds 1 directorship: Scl Lifesciences Limited (Whole-Time Director, since 04 Oct 2005, revenue ₹305 Cr (FY 2026)).
Udayan Sengupta was first appointed on 04 Oct 2005 as Whole-Time Director at Scl Lifesciences Limited.
The current boards of Udayan Sengupta's companies include Anil Chaudhry (Scl Lifesciences Limited), Naohiro Yoshida (Scl Lifesciences Limited), Nitish Mukherjee (Scl Lifesciences Limited), Parveen Goyal (Scl Lifesciences Limited), Sameer Singla (Scl Lifesciences Limited), Saurav Goyal (Scl Lifesciences Limited), among others.